BidaskClub downgraded shares of Axovant Sciences Ltd. (NYSE:AXON) from a hold rating to a sell rating in a research report report published on Thursday morning.

Several other equities research analysts have also recently commented on AXON. Piper Jaffray Companies reissued an overweight rating and set a $32.00 price target on shares of Axovant Sciences in a research report on Wednesday, April 12th. Oppenheimer Holdings, Inc. reissued an outperform rating and set a $26.00 price target (up from $20.00) on shares of Axovant Sciences in a research report on Friday, April 14th. Jefferies Group LLC reissued a buy rating and set a $31.00 price target on shares of Axovant Sciences in a research report on Tuesday, April 18th. CIBC boosted their price target on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a neutral rating in a research report on Tuesday, April 18th. Finally, Cowen and Company reissued an outperform rating and set a $30.00 price target (up from $22.00) on shares of Axovant Sciences in a research report on Tuesday, June 13th. Three investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. Axovant Sciences presently has an average rating of Buy and an average price target of $28.50.

Axovant Sciences (NYSE AXON) opened at 23.11 on Thursday. The company’s market capitalization is $2.48 billion. Axovant Sciences has a 12-month low of $11.01 and a 12-month high of $26.49. The firm’s 50-day moving average price is $22.78 and its 200 day moving average price is $18.42.

Axovant Sciences (NYSE:AXON) last issued its quarterly earnings results on Tuesday, June 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.02. On average, equities research analysts expect that Axovant Sciences will post ($2.20) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/axovant-sciences-ltd-axon-downgraded-by-bidaskclub-to-sell/1463488.html.

Several large investors have recently modified their holdings of AXON. Bank of America Corp DE boosted its stake in shares of Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Axovant Sciences during the fourth quarter worth $139,000. Oppenheimer & Co. Inc. bought a new stake in shares of Axovant Sciences during the first quarter worth $219,000. American International Group Inc. boosted its stake in shares of Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after buying an additional 2,789 shares during the last quarter. 94.44% of the stock is currently owned by institutional investors.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.